麻豆视频

Ubiquitous wearable technologies, like smartwatches, could help researchers better understand progressive neurological disorders like 笔补谤办颈苍蝉辞苍鈥檚 disease and speed up the approval of new therapies, a critical need given that no drugs exist to slow progression of the world鈥檚 fastest growing brain disease.

New research appearing today in the journal adds to growing evidence that widely used and user-friendly consumer devices, in this instance an Apple Watch paired with an iPhone, can detect changes in 笔补谤办颈苍蝉辞苍鈥檚 symptoms over time in individuals in the early stages of the disease.

鈥淒igital measures hold the promise to provide objective, sensitive, real-world measures of disease progression in 笔补谤办颈苍蝉辞苍鈥檚 disease,鈥� said Jamie Adams, MD, an associate professor of Neurology at the 麻豆视频, the Center for Health + Technology, and lead author of the study. 鈥淭his study shows that data generated by smartwatches and smartphones can remotely monitor and detect changes in multiple domains of the disease. These digital assessments could help evaluate the efficacy of future therapies.鈥�

笔补谤办颈苍蝉辞苍鈥檚 is a complex disease, and the onset and severity of symptoms and progression varies widely from patient to patient. Traditional tools employed to track the disease are often subjective and collect information episodically during clinic visits. As a result, these tools do not adequately portray the day-to-day experience of individuals with 笔补谤办颈苍蝉辞苍鈥檚, limitations that have contributed to the slow pace of new therapies.

In contrast, smartwatches and smartphones can passively monitor many of the symptoms of the disease, such as gait and tremor. Additional information can be collected through tasks such as finger tapping and voice recording to measure speech-related symptoms. Adams and her colleagues recently demonstrated the devices could detect differences between individuals with early, untreated 笔补谤办颈苍蝉辞苍鈥檚 and age-matched controls.

The smartwatch was able to detect decreases in arm swing, a common clinical feature of the disease, and activity in the form of the number of daily steps. The progression of symptoms in individuals in the study was consistent with other long-term studies of the disease.

The study was designed to replicate a multi-center clinical trial in individuals with early and untreated 笔补谤办颈苍蝉辞苍鈥檚 disease and involved the participation and input from the pharmaceutical industry, regulators, investigators, and individuals with disease. The WATCH-PD study has recently been and will follow participants for an additional 18 months.

鈥淥n behalf of Critical Path Institute, we are delighted to see the astounding progress of this unique project,鈥� said Diane Stephenson, PhD, executive director of consortium and co-author of the study. 鈥淭he early and often feedback from regulators have shaped this study in ways that now can link the clinical meaningfulness of symptoms measured by digital health technologies to the voice of people with lived experience. By partnering with patients, regulators, industry, and academic experts this project is serving as a precedent for other disease areas to follow.鈥�

Additional authors include Ray Dorsey, Melissa Kostrzebski, Peggy Auinger, Peter Wilmot, Yvonne Pohlson, and Stella Jensen-Roberts with URMC; Tairmae Kangarloo, Yishu Gong, Vahe Khachadourian, Brian Tracey, Dmitri Volfson, and Robert Latzman with Takeda Pharmaceuticals; Martijn M眉ller with the Critical Path Institute; Joshua Cosman with AbbVie Pharmaceuticals; Jeremy Edgerton with Biogen; David Anderson and Allen Best with Clinical Ink; and the Parkinson Study Group Watch-PD Study investigators and collaborators including Christopher Tarolli from URMC. The research was supported with funding from Biogen, Takeda, and the members of the Critical Path for 笔补谤办颈苍蝉辞苍鈥檚 Consortium.